Research Article

Hubungan antara terapi statin dengan kadar gula darah puasa dan profil lipid pada pasien coronary artery disease di RSUD Sanjiwani

I Gusti Ayu Inten Heny Pratiwi , Ketut Erna Bagiari, I Gede Bagus Gita Pranata Putra

I Gusti Ayu Inten Heny Pratiwi
Dokter Magang Bagian Ilmu Penyakit Dalam Divisi Kardiologi dan Kedokteran Vaskular RSUD Sanjiwani Gianyar, Bali. Email: intenheny@gmail.com

Ketut Erna Bagiari
Bagian Ilmu Penyakit Dalam Divisi Kardiologi dan Kedokteran Vaskular RSUD Sanjiwani Gianyar, Bali

I Gede Bagus Gita Pranata Putra
Bagian Ilmu Penyakit Dalam Divisi Kardiologi dan Kedokteran Vaskular RSUD Sanjiwani Gianyar, Bali ; Fakultas Kedokteran dan Ilmu Kesehatan Universitas Warmadewa
Online First: April 01, 2021 | Cite this Article
Pratiwi, I., Bagiari, K., Putra, I. 2021. Hubungan antara terapi statin dengan kadar gula darah puasa dan profil lipid pada pasien coronary artery disease di RSUD Sanjiwani. Intisari Sains Medis 12(1): 55-59. DOI:10.15562/ism.v12i1.953


Background: Statin therapy has an important role to coronary artery disease (CAD) which can lowered cholesterol levels and give pleiotropic effects to inhibit inflammatory reactions. Statin have some side effects and new onset diabetes is one of them, where diabetes is also a risk factor for CAD. This study aims to know the correlation of statin therapy and fasting blood glucose levels of CAD patient in Sanjiwani Hospital.

Methods: The design of this study was analytic cross-sectional study that started from November 17th 2020 until January 31st 2021 in Sanjiwani Hospital. A total of 68 patients were included in this study. The data source of this study was secondary data from patient’s medical record. The inclusion criteria was all CAD patients with statin therapy who had history of fasting blood glucose test that visited cardiology department of Sanjiwani Hospital at year 2020. Normality test, bivariate, and multivariate analysis was done in this study.

Results: Bivariate analysis using Spearman showed a weak positive correlation between duration of statin therapy with fasting blood glucose levels (r=0,353; p= 0,003), and Kruskal Wallis analysis showed no correlation between statin type with fasting blood glucose levels.

Conclusion: Duration of statin therapy has a weak correlation with fasting blood glucose levels so that statin still can be given with concerns to its benefit of reduced mortality. Prevention of new onset diabetes should be done by lifestyle modification and periodic blood glucose monitoring.

 

 

Latar Belakang: Terapi statin memiliki peranan penting terhadap coronary artery disease (CAD) yang mampu menurunkan kadar kolesterol serta memberikan efek pleiotropik untuk menghambat reaksi inflamasi. Statin memiliki beberapa efek samping, salah satunya adalah risiko diabetes onset baru dimana diabetes merupakan salah satu faktor risiko CAD. Penelitian ini dilakukan untuk mengetahui hubungan antara terapi statin dengan kadar gula darah puasa pasien CAD di RSUD Sanjiwani.

Metode: Desain penelitian yang digunakan adalah analitik cross-sectional yang dilakukan dari 17 November 2020 sampai 31 Januari 2021 di RSUD Sanjiwani. Sebanyak 68 pasien diikutkan dalam penelitian ini. Sumber data pada penelitian ini berupa data sekunder yang didapatkan dari rekam medis pasien dengan kriteria inklusi yaitu semua pasien CAD dengan terapi statin dan memiliki riwayat pemeriksaan kadar gula darah puasa yang melakukan kontrol di poli jantung RSUD Sanjiwani tahun 2020. Uji normalitas, analisis bivariat, dan multivariat dilakukan pada penelitian ini.

Hasil: Analisis bivariat dengan Spearman menunjukan adanya korelasi positif lemah antara durasi terapi statin dengan kadar gula darah puasa (r=0,353; p= 0,003), sedangkan hasil analisis Kruskall Wallis menunjukan tidak ada korelasi antara jenis statin dengan kadar gula darah puasa.

Simpulan: Durasi terapi statin memiliki hubungan lemah dengan kadar gula darah puasa sehingga terapi statin masih dapat diberikan dengan memperhatikan keuntungan terapi yang lebih besar. Pencegahan terhadap risiko diabetes onset baru tetap dilakukan dengan modifikasi gaya hidup serta pemantauan gula darah berkala.

References

Liu MB. Cardiovascular diseases. Chinese Medical Journal. 2014;125:6–7.

CDC. Heart Disease Facts & Statistic. Cdc. 2016.

Badan Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan RI. Riset Kesehatan Dasar 2013. 2013.

Knuuti J, Wijns W, Achenbach S, Agewall S, Barbato E, Bax JJ, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.

Li M, Wang X, Li X, Chen H, Hu Y, Zhang X, et al. Statins for the Primary Prevention of Coronary Heart Disease. Biomed Res Int. 2019;1-15.

Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812–23.

Wengrofsky P, Lee J, N. Makaryus A. Dyslipidemia and Its Role in the Pathogenesis of Atherosclerotic Cardiovascular Disease: Implications for Evaluation and Targets for Treatment of Dyslipidemia Based on Recent Guidelines. Dyslipidemia. 2019;1-19.

Mahalle N, Garg M, Naik S, Kulkarni M. Study of pattern of dyslipidemia and its correlation with cardiovascular risk factors in patients with proven coronary artery disease. Indian J Endocrinol Metab. 2014;18(1):48–55.

Hedayatnia M, Asadi Z, Zare-Feyzabadi R, Yaghooti-Khorasani M, Ghazizadeh H, Ghaffarian-Zirak R, et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis. 2020;19(1):1–11.

Khashayar P, Mohagheghi A. The correlation between dyslipidemia and coronary artery disease based on angiographic findings in an Iranian population. Acta Med Indones. 2010;42(2):82–5.

Moriya J. Critical roles of inflammation in atherosclerosis. J Cardiol. 2019;73(1):22–7.

Nakagawa Y. Role of statins in coronary artery disease. Nihon Rinsho. 2016;74(1):400–4.

Diamantis E, Kyriakos G, Quiles-Sanchez LV, Farmaki P, Troupis T. The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature. Curr Cardiol Rev. 2017;13(3):209–16.

FDA. Important safety label changes to cholesterol-lowering statin drugs. FDA Drug Safety Communication. 2012.

Ko MJ, Jo AJ, Kim YJ, Kang SH, Cho S, Jo SH, et al. Time- and Dose-Dependent Association of Statin Use With Risk of Clinically Relevant New-Onset Diabetes Mellitus in Primary Prevention: A Nationwide Observational Cohort Study. J Am Heart Assoc. 2019;8(8).

Lee G, Kim SM, Choi S, Kim K, Jeong SM, Son JS, et al. The effect of change in fasting glucose on the risk of myocardial infarction , stroke , and all ? cause mortality : a nationwide cohort study. Cardiovasc Diabetol. 2018;1–10.

Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, et al. Statin use and risk of developing diabetes : results from the Diabetes Prevention Program. 2017;1-8.

Sukhija R, Prayaga S, Marashdeh M, Bursac Z. Effect of Statins on Fasting Plasma Glucose in Diabetic and Nondiabetic Patients. 2009;57(3):495–500.

Bozorgmanesh M, Hadaegh F, Ghaffari S, Harati H, Azizi F. A simple risk score effectively predicted type 2 diabetes in Iranian adult population : population-based cohort study. 2010;21(5):554–9.

Mozaffary A, Asgari S, Tohidi M, Kazempour-ardebili S, Azizi F, Hadaegh F. Change in fasting plasma glucose and incident type 2 diabetes mellitus : results from a prospective cohort study. 2016;1–7.

Rao KNSVC, Vankayala A, Sayana SB, Raju DSSK. Effect of statins treatment on glycemic status and development of new onset diabetes mellitus in a tertiary care teaching hospital : a cross sectional study. 2019;6(3):706–12.

Ahmadizar F, Muka T, Stricker BH. Associations of statin use with glycaemic traits and incident type 2 diabetes. 2019;993–1002.

Galicia-garcia U, Jebari S, Larrea-sebal A, Uribe KB, Siddiqi H. Statin Treatment-Induced Development of Type 2 Diabetes : From Clinical Evidence to Mechanistic Insights. Int J Mol Sci. 2020;21(13):4725.

Colbert JD, Stone JA. Statin Use and the Risk of Incident Diabetes Mellitus: A Review of the Literature. Can J Cardiol. 2012;28(5):581–9.

Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556-2564

Wang HJ, Park JY, Kwon O, Choe EY, Kim CH, Hur KY, et al. Chronic HMGCR / HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction Chronic HMGCR / HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction. 2015;8627.

Nakata AM. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 ( SLC2A4 ): implications in glycaemic control. 2006;1881–92.

Zhao W. Different effects of statins on induction of diabetes mellitus : an experimental study. 2015;6211–23.

Soucek F, Covassin N, Singh P, et al. Effects of Atorvastatin (80 mg) Therapy on Quantity of Epicardial Adipose Tissue in Patients Undergoing Pulmonary Vein Isolation for Atrial Fibrillation. Am J Cardiol. 2015;116(9):1443-1446.

Bergeron J, Mancini GBJ, Baker S, Bergeron J, Fitchett D, Frohlich J, et al. Diagnosis , Prevention , and Management of Statin Adverse Effects and Diagnosis , Prevention , and Management of Statin Adverse Effects and Intolerance : Canadian Consensus Working Group Update ( 2016 ). Can J Cardiol. 2016;32(7):35–65.

Betteridge DJ, Carmena R. The diabetogenic action of statins - mechanisms and clinical implications. Nat Rev Endocrinol. 2016;12(2):99-110.

Brault M, Ray J, Gomez Y, Mantzoros CS, Daskalopoulou SS. of proposed mechanisms. Metabolism. 2014;63(6):735–45.

Khan SU, Rahman H, Okunrintemi V, Riaz H, Khan MS, Sattur S, et al. Association of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering therapies and risk of diabetes mellitus: A systematic review and meta-analysis. J Am Heart Assoc. 2019;8(7).

Wang S, Cai R, Yuan Y, Varghese Z, Moorhead J, Ruan XZ. Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: A meta-analysis. Sci Rep. 2017;7:1–9.

Sudrajad GB, Kusuma AS, Kusumaratna RK. Paradigma baru penggunaan statin: efek kardioprotektif atau penyebab onset baru diabetes melitus?. J Biomedika Kesehat. 2020;3(2):101-8.

Florido R, Elander A, Blumenthal RS, Martin SS. Statins and Incident Diabetes : Can Risk Outweigh Benefit? Curr Cardiovasc Risk Rep. 2015; 9(14):1–7.

Aiman U, Najmi A, Khan RA. Statin induced diabetes and its clinical implications. J Pharmacol Pharmacother. 2014;5(3):181–5.

Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet. 2012;380(9841):565–71.


Article Views      : 486
PDF Downloads : 237